Ocular affectations produced by the Covid-19 disease. Review
Keywords:
Covid 19, SARS-CoV-2, Ophthalmological affectations.Abstract
This review was intended to cover of the existing publications up to the moment which inform about the ophthalmological affectations of the COVID-19 disease, caused by the new coronavirus or severe acute respiratory syndrome 2 (SARS-CoV-2). It was carried out a search in PubMed/Medline until 28/02/2021, the following publications in English were revised: letters to the editor, clinical cases, bibliographic review and clinical studies. In the search field was included both, the abstract and the title of the publication. As ocular affectations produced by the covid-19 were found the viral conjunctivitis, immune-mediated conjunctivitis, oculomotors paralysis (POM) and uveitis. The possibility of retinopathy is raised. Ophthalmologists are at considerable risk of contracting the COVID-19 due to close contact with the patient, exposure to tears and ocular secretions, as well as the use of equipment and devices capable of get contaminated.
Downloads
References
1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13): 1199-207.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727-33.
3. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020; 395(10231): 1225-8.
4. Sahin A, Erdogan A, Mutlu Agaoglu P, Dineri Y, Cakirci A, Senel M, et al. 2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. EJMO. 2020; 4(1): 1-7.
5. Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet. 2020; 395(10224): e39.
6. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367(6485): 1444-8.
7. Chen L, Liu M, Zhang Z, Qiao K, Huang T, Chen M, et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. Br J Ophthalmol. 2020; 104(6): 748-51.
8. Latalska M, Mackiewicz J. Erratum to the article: The implication of ocular manifestation of COVID-19 for medical staff and patients - systematic review. Ann Agric Environ Med. 2020; 27(3): 489.
9. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020; 92(6): 589-94.
10. Shetty R, D'Souza S, Lalgudi VG. What ophthalmologists should know about conjunctivitis in the COVID-19 pandemic? Indian J Ophthalmol. 2020; 68(5): 683-7.
11. Jun Seah IY, Anderson DE, Zheng Kang AE, Wang L, Rao P, Young BE, et al. Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients. Ophthalmology. 2020l; 127(7): 977-9.
12. Zhang X, Chen X, Chen L, Deng C, Zou X, Liu W, et al. The evidence of SARS-CoV-2 infection on ocular surface. Ocul Surf. 2020; 18(3): 360-2.
13. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020; 138(5): 575-8.
14. Ulhaq ZS, Soraya GV. The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid. Graefes Arch Clin Exp Ophthalmol. 2020; 258(6): 1351-2.
15. Zhou Y, Zeng Y, Tong Y, Chen C. Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva. medRxiv. [Internet]. 2020 [citado 29/06/2022]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.02.11.20021956v1.full.pdf.
16. Tong T, Lai TS. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol. 2005; 89(3): 392-3.
17. Chentoufi AA, Dasgupta G, Nesburn AB, Bettahi I, Binder NR, Choudhury ZS, et al. Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization. Clin Vaccine Immunol. 2010; 17(3): 342-53.
18. Nickbakhsh S, Mair C, Matthews L, Reeve R, Johnson PCD, Thorburn F. Virus-virus interactions impact the population dynamics of influenza and the common cold. Proc Natl Acad Sci U S A. 2019; 116(52): 27142–50.
19. Brodin P. Why is COVID-19 so mild in children? Acta Paediatr. 2020; 109(6): 1082-3.
20. Chen L, Liu M, Zhang Z, Qiao K, Huang T, Chen M, et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. Br J Ophthalmol. 2020; 104(6): 748-51.
21. Cheema M, Aghazadeh H, Nazarali S, Ting A, Hodges J, McFarlane A, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). Can J Ophthalmol. 2020; (4): e125-e9.
22. Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm. 2020; 28(3): 391-5.
23. Asadi Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020; 413: 116832.
24. Munayco Guillén F, Fernández Poma SM, Nakagawa Yep II, Aguirre Rocca CJ. Manifestaciones oculares en la enfermedad por coronavirus SARS-CoV-2. ¿Qué sabemos? Rev Med Hered. 2020; 31(3): 203-4.
25. Guerra Almaguer M, Cárdenas Díaz T, Ramos López M, Pérez Suárez RG, Vigoa Aranguren L. Manifestaciones oftalmológicas de la COVID-19. Rev Cubana Oftalmol. 2020; 33(2): e943-e52.

Downloads
Published
How to Cite
Issue
Section
License
Avisos de derechos de autor propuestos por Creative Commons
1. Política propuesta para revistas que ofrecen acceso abierto
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).